OrbiMed Advisors
Latest statistics and disclosures from Orbimed Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are EWTX, ELVN, RCEL, MDXH, LLY, and represent 31.16% of Orbimed Advisors's stock portfolio.
- Added to shares of these 10 stocks: RCEL (+$303M), MDXH (+$286M), AZN (+$132M), MYGN (+$123M), MRK (+$80M), GH (+$40M), XENE (+$36M), MLYS (+$29M), PRAX (+$25M), PVLA (+$23M).
- Started 26 new stock positions in NKTR, AMGN, AZN, LFST, AORT, GILD, MDXH, STRO, QGEN, ATAI.
- Reduced shares in these 10 stocks: TERN (-$87M), EW (-$61M), APLS (-$61M), LLY (-$59M), CI (-$56M), ALNY (-$56M), RAPT (-$56M), , ROIV (-$48M), SYK (-$47M).
- Sold out of its positions in FOLD, APLS, Avidity Biosciences Ord, BRKR, CI, CELC, CTMX, EXACT Sciences Corporation, INSM, MPLT. MNMD, NBIX, OCUL, PMVP, RAPT, Repare Therapeutics Ord, TARS, TERN, UTHR, VIR, ROIV.
- Orbimed Advisors was a net buyer of stock by $317M.
- Orbimed Advisors has $5.2B in assets under management (AUM), dropping by 4.85%.
- Central Index Key (CIK): 0001055951
Tip: Access up to 7 years of quarterly data
Positions held by OrbiMed Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Orbimed Advisors
Orbimed Advisors holds 110 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Edgewise Therapeutics (EWTX) | 9.5 | $489M | 16M | 31.50 |
|
|
| Enliven Therapeutics (ELVN) | 6.0 | $312M | 8.0M | 39.20 |
|
|
| Avita Therapeutics (RCEL) | 5.9 | $303M | NEW | 82M | 3.70 |
|
| Mdxhealth Sa Shs New Call Option (MDXH) | 5.5 | $286M | NEW | 124M | 2.30 |
|
| Eli Lilly & Co. (LLY) | 4.2 | $218M | -21% | 237k | 919.77 |
|
| Sinovac Biotech SHS | 3.6 | $185M | 2.7M | 67.85 |
|
|
| Boston Scientific Corporation (BSX) | 2.9 | $150M | 2.4M | 62.75 |
|
|
| Sionna Therapeutics (SION) | 2.7 | $142M | 3.5M | 40.09 |
|
|
| Astrazeneca Ord (AZN) | 2.6 | $132M | NEW | 670k | 197.22 |
|
| Myriad Genetics (Principal) (MYGN) | 2.4 | $123M | NEW | 125M | 0.98 |
|
| Mbx Biosciences (MBX) | 2.1 | $109M | -7% | 3.6M | 29.85 |
|
| Corvus Pharmaceuticals (CRVS) | 2.0 | $105M | 7.2M | 14.63 |
|
|
| Argenx Se Sponsored Adr (ARGX) | 1.9 | $100M | -6% | 137k | 730.25 |
|
| Edwards Lifesciences (EW) | 1.9 | $99M | -38% | 1.2M | 80.08 |
|
| Intuitive Surgical Com New (ISRG) | 1.9 | $96M | -20% | 209k | 460.99 |
|
| Compass Therapeutics (CMPX) | 1.6 | $81M | 15M | 5.29 |
|
|
| Merck & Co (MRK) | 1.5 | $80M | NEW | 663k | 120.29 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.4 | $71M | +26% | 1.5M | 48.20 |
|
| Arrivent Biopharma (AVBP) | 1.4 | $70M | 3.0M | 23.07 |
|
|
| Disc Medicine (IRON) | 1.3 | $68M | 1.1M | 63.94 |
|
|
| Silverback Therapeutics (SPRY) | 1.3 | $67M | 8.3M | 8.03 |
|
|
| Cg Oncology (CGON) | 1.2 | $64M | -37% | 948k | 67.68 |
|
| Xenon Pharmaceuticals (XENE) | 1.2 | $62M | +137% | 1.1M | 58.15 |
|
| Stryker Corporation (SYK) | 1.2 | $60M | -43% | 183k | 328.59 |
|
| Bristol Myers Squibb (BMY) | 1.1 | $56M | +19% | 925k | 60.65 |
|
| Mineralys Therapeutics (MLYS) | 1.1 | $56M | +109% | 2.1M | 27.09 |
|
| Praxis Precision Medicines I Com New (PRAX) | 1.1 | $56M | +82% | 173k | 322.19 |
|
| Pfizer (PFE) | 1.1 | $55M | +17% | 1.9M | 28.08 |
|
| Dyne Therapeutics (DYN) | 1.0 | $53M | +32% | 2.9M | 18.13 |
|
| Natera (NTRA) | 1.0 | $52M | -28% | 262k | 199.99 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.0 | $52M | +26% | 466k | 111.35 |
|
| Upstream Bio (UPB) | 1.0 | $51M | 5.7M | 9.00 |
|
|
| Danaher Corporation (DHR) | 1.0 | $50M | -11% | 266k | 189.60 |
|
| Caris Life Sciences (CAI) | 1.0 | $50M | -9% | 2.8M | 17.88 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.8 | $42M | +5% | 182k | 228.73 |
|
| Shattuck Labs (STTK) | 0.8 | $41M | 6.3M | 6.43 |
|
|
| Guardant Health (GH) | 0.8 | $40M | NEW | 435k | 92.37 |
|
| Alnylam Pharmaceuticals (ALNY) | 0.8 | $39M | -58% | 119k | 330.87 |
|
| Prelude Therapeutics (PRLD) | 0.7 | $37M | 11M | 3.42 |
|
|
| Crinetics Pharmaceuticals In (CRNX) | 0.7 | $36M | 999k | 36.32 |
|
|
| Axsome Therapeutics (AXSM) | 0.7 | $36M | -15% | 214k | 169.02 |
|
| Uniqure Nv SHS (QURE) | 0.7 | $35M | +189% | 2.1M | 16.35 |
|
| Oric Pharmaceuticals (ORIC) | 0.7 | $34M | -26% | 2.7M | 12.67 |
|
| Anthem (ELV) | 0.7 | $34M | +15% | 115k | 292.75 |
|
| Relmada Therapeutics (RLMD) | 0.6 | $33M | +80% | 4.7M | 6.96 |
|
| Imagenebio Nonvoting | 0.6 | $31M | 6.2M | 5.00 |
|
|
| Forte Biosciences Com New (FBRX) | 0.6 | $31M | 1.2M | 25.90 |
|
|
| Trevi Therapeutics (TRVI) | 0.6 | $29M | -23% | 2.5M | 11.93 |
|
| Esperion Therapeutics (ESPR) | 0.6 | $29M | +77% | 11M | 2.74 |
|
| Neuropace (NPCE) | 0.5 | $28M | -12% | 2.1M | 13.15 |
|
| Rhythm Pharmaceuticals (RYTM) | 0.5 | $27M | +30% | 314k | 86.97 |
|
| Palvella Therapeutics Inc Ne (PVLA) | 0.4 | $23M | NEW | 185k | 124.65 |
|
| Thermo Fisher Scientific (TMO) | 0.4 | $23M | 47k | 491.53 |
|
|
| Syndax Pharmaceuticals (SNDX) | 0.4 | $23M | NEW | 962k | 23.36 |
|
| Brightspring Health Svcs (BTSG) | 0.4 | $21M | 498k | 42.61 |
|
|
| Lexeo Therapeutics (LXEO) | 0.4 | $21M | +69% | 3.6M | 5.74 |
|
| Sutro Biopharma Com Shs (STRO) | 0.4 | $20M | NEW | 801k | 24.91 |
|
| Nektar Therapeutics Com New (NKTR) | 0.4 | $20M | NEW | 275k | 71.95 |
|
| Cybin Com New (HELP) | 0.4 | $18M | 3.8M | 4.80 |
|
|
| Krystal Biotech (KRYS) | 0.3 | $18M | -42% | 69k | 258.32 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 0.3 | $16M | +8% | 1.7M | 9.39 |
|
| Urogen Pharma (URGN) | 0.3 | $16M | 876k | 17.98 |
|
|
| Definium Therapeutics Com Shs (DFTX) | 0.3 | $15M | NEW | 804k | 18.90 |
|
| Vera Therapeutics Cl A (VERA) | 0.3 | $15M | +4% | 370k | 40.23 |
|
| Q32 Bio (QTTB) | 0.3 | $15M | 2.3M | 6.42 |
|
|
| Aadi Bioscience (WHWK) | 0.3 | $14M | 4.2M | 3.45 |
|
|
| Amgen (AMGN) | 0.3 | $14M | NEW | 40k | 351.85 |
|
| Alignment Healthcare (ALHC) | 0.3 | $14M | NEW | 791k | 17.62 |
|
| Eyepoint Com New (EYPT) | 0.3 | $14M | -56% | 1.1M | 12.89 |
|
| Janux Therapeutics (JANX) | 0.3 | $14M | -49% | 984k | 13.90 |
|
| BioCryst Pharmaceuticals (BCRX) | 0.3 | $14M | -18% | 1.4M | 9.52 |
|
| Bicara Therapeutics (BCAX) | 0.3 | $13M | +219% | 667k | 19.89 |
|
| Bioage Labs (BIOA) | 0.2 | $12M | -9% | 712k | 17.49 |
|
| Cogent Biosciences (COGT) | 0.2 | $12M | -13% | 322k | 38.49 |
|
| Alumis (ALMS) | 0.2 | $12M | -50% | 548k | 22.03 |
|
| Regeneron Pharmaceuticals (REGN) | 0.2 | $11M | NEW | 15k | 772.64 |
|
| Carlsmed (CARL) | 0.2 | $11M | 1.3M | 9.05 |
|
|
| Biogen Idec (BIIB) | 0.2 | $11M | NEW | 62k | 183.33 |
|
| Qiagen Nv Ord Shares Call Option (QGEN) | 0.2 | $10M | NEW | 250k | 40.04 |
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 0.2 | $8.7M | -3% | 181k | 48.15 |
|
| Keros Therapeutics (KROS) | 0.2 | $8.4M | -5% | 759k | 11.04 |
|
| Gilead Sciences (GILD) | 0.2 | $8.3M | NEW | 60k | 139.37 |
|
| Heron Therapeutics (HRTX) | 0.2 | $7.9M | NEW | 9.8M | 0.80 |
|
| Avalo Therapeutics Com New (AVTX) | 0.1 | $7.1M | -59% | 475k | 14.93 |
|
| Tectonic Therapeutic (TECX) | 0.1 | $7.0M | -60% | 227k | 30.91 |
|
| Adicet Bio Com New (ACET) | 0.1 | $7.0M | 1.0M | 6.81 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 0.1 | $6.4M | NEW | 1.2M | 5.53 |
|
| Pharvaris N V (PHVS) | 0.1 | $5.8M | 205k | 28.25 |
|
|
| Alx Oncology Hldgs (ALXO) | 0.1 | $5.7M | NEW | 2.9M | 2.00 |
|
| CryoLife (AORT) | 0.1 | $5.5M | NEW | 151k | 36.62 |
|
| Inspiremd (NSPR) | 0.1 | $5.1M | 3.1M | 1.63 |
|
|
| Revolution Medicines (RVMD) | 0.1 | $5.1M | +100% | 52k | 97.25 |
|
| Adc Therapeutics Sa SHS (ADCT) | 0.1 | $4.9M | -77% | 1.3M | 3.75 |
|
| Protagonist Therapeutics (PTGX) | 0.1 | $4.4M | +94% | 42k | 105.40 |
|
| Palisade Bio (PALI) | 0.1 | $4.1M | +24% | 2.3M | 1.75 |
|
| Alto Neuroscience Com Shs (ANRO) | 0.1 | $3.8M | +34% | 168k | 22.48 |
|
| Savara (SVRA) | 0.1 | $3.5M | NEW | 635k | 5.46 |
|
| Cullinan Oncology (CGEM) | 0.1 | $3.5M | -9% | 243k | 14.21 |
|
| Soleno Therapeutics Call Option (SLNO) | 0.1 | $3.3M | NEW | 100k | 33.48 |
|
| Ptc Therapeutics I (PTCT) | 0.1 | $3.3M | +111% | 49k | 68.13 |
|
| Lifestance Health Group (LFST) | 0.1 | $3.2M | NEW | 500k | 6.37 |
|
| Bright Minds Biosciences Com New (DRUG) | 0.1 | $2.9M | NEW | 40k | 72.97 |
|
| Jade Biosciences Com New (JBIO) | 0.1 | $2.6M | -65% | 185k | 14.05 |
|
| C4 Therapeutics Com Stk (CCCC) | 0.0 | $2.3M | -39% | 856k | 2.63 |
|
| Kalvista Pharmaceuticals (KALV) | 0.0 | $1.9M | -75% | 94k | 20.13 |
|
| Imagenebio (IMA) | 0.0 | $1.9M | 379k | 5.00 |
|
|
| Vistagen Therapeutics Ord (VTGN) | 0.0 | $1.7M | 3.1M | 0.57 |
|
|
| Ataibeckley Com Shs (ATAI) | 0.0 | $1.2M | NEW | 347k | 3.54 |
|
| Cogent Biosciences Note 1.625%11/1 (Principal) | 0.0 | $1.2M | 1.0M | 1.22 |
|
|
| Traws Pharma Com New (TRAW) | 0.0 | $1.1M | 606k | 1.83 |
|
Past Filings by Orbimed Advisors
SEC 13F filings are viewable for Orbimed Advisors going back to 2010
- Orbimed Advisors 2026 Q1 filed May 15, 2026
- Orbimed Advisors 2025 Q4 filed Feb. 17, 2026
- Orbimed Advisors 2025 Q3 filed Nov. 14, 2025
- Orbimed Advisors 2025 Q2 filed Aug. 14, 2025
- Orbimed Advisors 2025 Q1 filed May 15, 2025
- Orbimed Advisors 2024 Q4 filed Feb. 14, 2025
- Orbimed Advisors 2024 Q3 filed Nov. 14, 2024
- Orbimed Advisors 2024 Q2 filed Aug. 14, 2024
- Orbimed Advisors 2024 Q1 filed May 15, 2024
- Orbimed Advisors 2023 Q4 filed Feb. 14, 2024
- Orbimed Advisors 2023 Q3 filed Nov. 14, 2023
- Orbimed Advisors 2023 Q2 filed Aug. 14, 2023
- Orbimed Advisors 2023 Q1 filed May 15, 2023
- Orbimed Advisors 2022 Q4 filed Feb. 14, 2023
- Orbimed Advisors 2022 Q3 filed Nov. 14, 2022
- Orbimed Advisors 2022 Q2 filed Aug. 15, 2022